By: Benzinga
UPDATE: Canaccord Genuity Raises PT to $44 on Aegerion Pharmaceuticals on Encouraging Sales Data
Canaccord Genuity maintained Aegerion Pharmaceuticals (NASDAQ: AEGR ) with a Buy rating and raised the price target from $36.00 to $44.00. Canaccord Genuity commented, "On the Q4 EPS call, AEGR provided metrics on the first six weeks of the Juxtapid launch in HoFH. The key takeaway was 400+ vs. 1800-targeted
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here